▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / PMCB

PMCB — PharmaCyte Biotech, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1157075 ·
Last close
$0.52
Market Cap
$5.64M
52W High
$0.87
52W Low
$0.50
ADV30
121,810
Next earnings
—
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Apr 2026 0 — -961,828 -4,393,443 46,753,242 18,603,899 11,772,424
Jan 2026 0 — -2,118,102 746,860 55,873,565 20,165,535 16,471,229
Oct 2025 0 — -1,376,051 -7,417,975 55,976,469 15,406,017 19,422,384
Jul 2025 0 — -848,305 -8,360,096 45,110,453 13,178,305 1,518,865

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,800,723
Investing CF
$2,000,000
Financing CF
$6,579,852
CapEx
—
Dividends Paid
—
Buybacks
$-735,774
EPS Diluted TTM
$-3.08
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-100,000,171
Inventory
—
Receivables
$0
ST Investments
$372,251
EBIT TTM
$-5,384,322
Pretax Income TTM
$-3,281,629
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Apr 2026 0 -5,304,286 -19,424,654 46,753,242 11,772,424 — -5,152,914
Apr 2025 0 -4,377,862 30,656,050 55,168,353 3,277,284 — -2,978,296
Apr 2024 0 -6,520,008 333,763 59,903,883 20,389,264 — -2,151,457
Apr 2023 0 -6,455,494 -4,315,993 73,276,925 586,581 — -3,793,731
Apr 2022 0 -4,392,014 -4,239,161 90,624,136 704,370 — -4,117,319

TTM Snapshot

Revenues TTM
$6,626
NetIncome TTM
$-510,517
OpCashFlow TTM
$0
Assets (Latest)
$2,876,931
Forward EPS
$-0.38

Peers — same industry

TickerNameMarket CapLastDaily %
BCAB BioAtla, Inc. $5.46M $3.28 —
LIMN Liminatus Pharma, Inc. $6.27M $4.67 —
AIM AIM ImmunoTech Inc. $7.73M $0.25 —
CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. $7.98M $1.21 —
VIVS VivoSim Labs, INC. $3.91M $0.29 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →